Details for New Drug Application (NDA): 208252
✉ Email this page to a colleague
The generic ingredient in AMBRISENTAN is ambrisentan. There are nine drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the ambrisentan profile page.
Summary for 208252
| Tradename: | AMBRISENTAN |
| Applicant: | Watson Labs Inc |
| Ingredient: | ambrisentan |
| Patents: | 0 |
Pharmacology for NDA: 208252
| Mechanism of Action | Endothelin Receptor Antagonists |
Suppliers and Packaging for NDA: 208252
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| AMBRISENTAN | ambrisentan | TABLET;ORAL | 208252 | ANDA | Actavis Pharma, Inc. | 0591-2405 | 0591-2405-30 | 30 TABLET, FILM COATED in 1 BOTTLE (0591-2405-30) |
| AMBRISENTAN | ambrisentan | TABLET;ORAL | 208252 | ANDA | Actavis Pharma, Inc. | 0591-2406 | 0591-2406-30 | 30 TABLET, FILM COATED in 1 BOTTLE (0591-2406-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
| Approval Date: | Mar 28, 2019 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
| Approval Date: | Mar 28, 2019 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
